FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs
The United States Food and Drug Administration has approved NUMELVI™ (atinvicitinib tablets), a new treatment for itch associated with allergic dermatitis in dogs, developed by Merck Animal Health. The company says the medication is the first and only second-generation Janus kinase (JAK) inhibitor approved in the United States for this indication.
MSD Animal Health Launches NUMELVI® (atinvicitinib) Tablets for Dogs – A Veterinary Innovation in Fast, Effective and Safe Targeted Itch Relief
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Commission (EC) has approved NUMELVI™ (atinvicitinib) Tablets for Dogs.